A team-based approach to reducing cardiac monitor alarms

A team-based approach can reduce excessive cardiac monitor alarms and therefore alarm desensitization and fatigue, according to a study published in Pediatrics.

Researchers from the Cincinnati Children's Hospital Medical Center created and implemented a standardized cardiac monitor care process (CMCP) on a 24-bed pediatric bone marrow transplant unit. The goal: decrease monitor alarms through team-based standardized care and processes, according to the study.

The team created and implemented a CMCP that included:

  1. A process for initial ordering of monitor parameters based on age-appropriate standards
  2. Pain-free daily replacement of electrodes
  3. Daily individualized assessment of cardiac monitor parameters
  4. A reliable method for appropriate discontinuation of monitor

The researchers utilized a model for improvement to design, test and implement changes. The changes that were implemented after testing and adaption were: family and patient engagement in the CMCP; creation of a monitor care log to address parameters; lead changes; discontinuation; development of a pain-free process for electrode removal; and customized monitor delay and customized threshold parameters, according to the study.

The intervention, which took place from January to November 2013, led to a decrease in the median number of alarms per patient-day from 180 to 40. “We recommend a team-based approach to monitor care, including individualized assessment of monitor parameters, daily lead change and proper discontinuation of the monitors,” concluded the authors.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.